Advanced search
Publication Cover
Current Medical Research and Opinion Volume 30, 2014 - Issue 6
Submit an article Journal homepage
736
Views
24
CrossRef citations to date
0
Altmetric
Research Articles

A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus

Yutaka SeinoKansai Electric Power Hospital OsakaJapanCorrespondence[email protected]
,
Nobuya InagakiKyoto University KyotoJapan
,
Hajime MiyaharaGlaxoSmithKline TokyoJapan
,
Inaha OkudaGlaxoSmithKline TokyoJapan
,
Mark BushNuventra Pharma Sciences Research Triangle Park, NCUSA (Nuventra Pharma Sciences was GlaxoSmithKline at the time of the development of this manuscript)
,
June YeGlaxoSmithKline Research Triangle Park, NCUSA
,
M. Claire HollandGlaxoSmithKline King of Prussia, PAUSA
,
Susan JohnsonGlaxoSmithKline Research Triangle Park, NCUSA
,
Eric LewisGlaxoSmithKline Research Triangle Park, NCUSA
&
Hiromu NakajimaGlaxoSmithKline TokyoJapan
 show all
Pages 1095-1106 | Accepted 16 Feb 2014, Published online: 11 Mar 2014

Citations (24)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (7)

Marc S. Rendell. (2018) Albiglutide for the management of type 2 diabetes. Expert Review of Endocrinology & Metabolism 13:1, pages 1-8.
Read now
Marc S. Rendell. (2017) The safety of albiglutide for the treatment of type 2 diabetes. Expert Opinion on Drug Safety 16:9, pages 1089-1097.
Read now
Inaha Okuda, Timothy H. Wilson, Lin Yue, Hiromu Nakajima, Molly C. Carr, Maho Tsuboi, Antonio Nino & Yutaka Seino. (2017) Albiglutide, a weekly GLP-1 receptor agonist, improves glycemic parameters in Japanese patients with type 2 diabetes over 1 year when added to single oral antidiabetic drugs. Current Medical Research and Opinion 33:3, pages 431-438.
Read now
Stephen L. Aronoff. (2017) Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes. Postgraduate Medicine 129:2, pages 231-241.
Read now
Jessica E. Matthews, Rickey R. Reinhardt & Molly C. Carr. (2016) Postprandial plasma glucose effects of once-weekly albiglutide for the treatment of type 2 diabetes. Postgraduate Medicine 128:4, pages 391-397.
Read now
L. Østergaard, Christian S. Frandsen & S. Madsbad. (2016) Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review. Expert Review of Clinical Pharmacology 9:2, pages 241-265.
Read now
Malcolm A. Young, Jeffrey A. Wald, Jessica E. Matthews, Rhona Scott, Rebecca J. Hodge, Hui Zhi & Rickey R. Reinhardt. (2014) Clinical Pharmacology of Albiglutide, a GLP-1 Receptor Agonist. Postgraduate Medicine 126:7, pages 84-97.
Read now

Articles from other publishers (17)

Shuzhen Bai, Chu Lin, Ruoyang Jiao, Xiaoling Cai, Suiyuan Hu, Fang Lv, Wenjia Yang, Xingyun Zhu & Linong Ji. (2023) Is the steady-state concentration, duration of action, or molecular weight of GLP-1RA associated with cardiovascular and renal outcomes in type 2 diabetes?. European Journal of Internal Medicine 109, pages 79-88.
Crossref
Lin Xia, Tiantian Shen, Wenliang Dong, Feng Su, Jiaxue Wang, Qian Wang, Suping Niu & Yi Fang. (2021) Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: A network meta-analysis. Diabetes Research and Clinical Practice 177, pages 108904.
Crossref
Chu Lin, Xiaoling Cai, Wenjia Yang, Fang Lv, Lin Nie & Linong Ji. (2020) Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus. BMC Medicine 18:1.
Crossref
Sanaz Kamalinia, Robert G. Josse, Patrick J. Donio, Lindsay Leduc, Baiju R. Shah & Sheldon W. Tobe. (2019) Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta‐analysis. Endocrinology, Diabetes & Metabolism 3:1.
Crossref
Antonio Nino, Inaha Okuda, Timothy H Wilson, Lynn Yue, Hiromu Nakajima, Maho Tsuboi, Molly C Carr & Yutaka Seino. (2018) Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study. Journal of Diabetes Investigation 9:3, pages 558-566.
Crossref
Sofie Hædersdal, Asger Lund, Filip K. Knop & Tina Vilsbøll. (2018) The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes. Mayo Clinic Proceedings 93:2, pages 217-239.
Crossref
Andreas Brønden, Filip K. Knop & Mikkel B. Christensen. (2017) Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide. Clinical Pharmacokinetics 56:7, pages 719-731.
Crossref
Bo Ahrén, Molly C. Carr, Karen Murphy, Christopher Perkins, Marc Rendell, Jason Mallory, Timothy Wilson & Susan Johnson. (2017) Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice 126, pages 230-239.
Crossref
Zhixia Li, Yuan Zhang, Xiaochi Quan, Zhirong Yang, Xiantao Zeng, Linong Ji, Feng Sun & Siyan Zhan. (2016) Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. PLOS ONE 11:5, pages e0154206.
Crossref
Je-Yon Kim, Seungwon Yang, Jangik I. Lee & Min Jung Chang. (2016) Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis. PLOS ONE 11:4, pages e0153502.
Crossref
Arun K. Sharma, Punniyakoti V. Thanikachalam & Satyendra K. Rajput. (2016) Albiglutide: Is a better hope against diabetes mellitus?. Biomedicine & Pharmacotherapy 77, pages 120-128.
Crossref
T. Karagiannis, A. Liakos, E. Bekiari, E. Athanasiadou, P. Paschos, D. Vasilakou, M. Mainou, M. Rika, P. Boura, D. R. Matthews & A. Tsapas. (2015) Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes, Obesity and Metabolism 17:11, pages 1065-1074.
Crossref
Miles Fisher, Mark C Petrie, Philip D Ambery, Jill Donaldson, June Ye & John J V McMurray. (2015) Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. The Lancet Diabetes & Endocrinology 3:9, pages 697-703.
Crossref
Portia N. Davis, Uche Anadu Ndefo, Ashley Oliver & Enryka Payton. (2015) Albiglutide: A once-weekly glucagon-like peptide-1 receptor agonist for type 2 diabetes mellitus. American Journal of Health-System Pharmacy 72:13, pages 1097-1103.
Crossref
Hannah A. Blair & Gillian M. Keating. (2015) Albiglutide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. Drugs 75:6, pages 651-663.
Crossref
Peter N. Weissman, Molly C. Carr, June Ye, Deborah T. Cirkel, Murray Stewart, Caroline Perry & Richard Pratley. (2014) HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea. Diabetologia 57:12, pages 2475-2484.
Crossref
Jennifer M. Trujillo & Wesley Nuffer. (2014) Albiglutide. Annals of Pharmacotherapy 48:11, pages 1494-1501.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.